Table 2. Representative sjTRECs and DβJβ... | American Society of Hematology

Table 2.

Representative sjTRECs and DβJβ TRECs frequencies in adults who did not undergo transplantation and AHSCT patients

Patients and identification nos.		Months after AHSCT	sjTRECs per 10⁵ CD3^*	Dβ1Jβ1.1 to Dβ1Jβ1.6 TRECs/10⁵ CD3⁺ cells†
Patients and identification nos.		Months after AHSCT	sjTRECs per 10⁵ CD3^*	Age, y			1.1	1.2	1.3	1.4	1.5	1.6
Controls who did not undergo transplantation
2	33	NA	1547‡	—	4	2	—	—	3
4	26	NA	1631	—	4	—	—	—	5
7	33	NA	3841	—	6	—	—	5	—
11	42	NA	346	2	—	1	3	—	9
13	37	NA	116	4	—	—	4	—	2
18	65	NA	23	—	—	—	—	—	—
24	40	NA	596	—	16	—	—	6	—
cGVHD⁻ AHSCT patients§
3	39	16	356	—	7	—	—	—	—
5	50	32	1348	11	—	9	—	—	28
6	41	108	814	3	—	—	—	1	—
13	42	48	869	4	—	—	—	—	—
20	25	30	3746	7	10	—	—	2	30
35	51	36	15	—	—	—	—	7	6
37	59	36	92	—	—	—	—	6	—
cGVHD⁺ AHSCT patients§
8	40	44	240	—	2	—	—	—	2
17	49	20	64	—	5	—	—	—	—
18	21	36	328	6	5	—	—	2	—
22	50	19	85	—	3	—	—	—	—
25	57	25	77	—	—	—	—	—	—
33	42	12	141	2	3	—	—	—	—
38	47	48	87	—	—	—	—	1	1

Patients and identification nos.		Months after AHSCT	sjTRECs per 10⁵ CD3^*	Dβ1Jβ1.1 to Dβ1Jβ1.6 TRECs/10⁵ CD3⁺ cells†
Patients and identification nos.		Months after AHSCT	sjTRECs per 10⁵ CD3^*	Age, y			1.1	1.2	1.3	1.4	1.5	1.6
Controls who did not undergo transplantation
2	33	NA	1547‡	—	4	2	—	—	3
4	26	NA	1631	—	4	—	—	—	5
7	33	NA	3841	—	6	—	—	5	—
11	42	NA	346	2	—	1	3	—	9
13	37	NA	116	4	—	—	4	—	2
18	65	NA	23	—	—	—	—	—	—
24	40	NA	596	—	16	—	—	6	—
cGVHD⁻ AHSCT patients§
3	39	16	356	—	7	—	—	—	—
5	50	32	1348	11	—	9	—	—	28
6	41	108	814	3	—	—	—	1	—
13	42	48	869	4	—	—	—	—	—
20	25	30	3746	7	10	—	—	2	30
35	51	36	15	—	—	—	—	7	6
37	59	36	92	—	—	—	—	6	—
cGVHD⁺ AHSCT patients§
8	40	44	240	—	2	—	—	—	2
17	49	20	64	—	5	—	—	—	—
18	21	36	328	6	5	—	—	2	—
22	50	19	85	—	3	—	—	—	—
25	57	25	77	—	—	—	—	—	—
33	42	12	141	2	3	—	—	—	—
38	47	48	87	—	—	—	—	1	1

NA indicates not applicable; —, less than 1.

sjTREC frequencies were normalized according to CD3⁺ T-lymphocyte proportions, as determined by flow cytometry.

†

TREC frequencies were normalized according to CD3⁺ T-lymphocyte proportions, as determined by flow cytometry. Similar results were obtained in a duplicate experiment.

‡

sjTREC content is shown as the mean of 2 independent quantifications.

AHSCT patients who underwent transplantation were classified according to their cGVHD history/status. cGVHD⁺ patients (n = 10) were symptomatic at sampling time, whereas cGVHD⁻ patients were exempt of symptoms since engraftment (n = 8) or for at least 8 months prior sampling (n = 14).

View Large

This Feature Is Available To Subscribers Only